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ula.Objective: A high protein content of nonhydrolyzed infant formula
exceeding metabolic requirements can induce rapid weight gain and
obesity. Hydrolyzed formula with too low protein (LP) content may
result in inadequate growth. The aim of this study was to investigate
noninferiority of partial and extensively hydrolyzed formulas (pHF, eHF)
with lower hydrolyzed protein content than conventionally, regularly
used formulas, with or without synbiotics for normal growth of healthy
term infants.
Methods: In an European multi-center, parallel, prospective, controlled,
double-blind trial, 402 formula-fed infants were randomly assigned to four
groups: LP-formulas (1.9 g protein/100 kcal) as pHF with or without
synbiotics, LP-eHF formula with synbiotics, or regular protein eHF (2.3 g
protein/100 kcal). One hundred and one breast-fed infants served as
observational reference group. As primary endpoint, noninferiority of
daily weight gain during the first 4 months of life was investigated
comparing the LP-group to a regular protein eHF group.
Results: A comparison of daily weight gain in infants receiving LPpHF
(2.15 g/day CI 0.18 to inf.) with infants receiving regular protein eHF
showed noninferior weight gain (3.5 g/day margin; per protocol [PP]
population). Noninferiority was also confirmed for the other tested LP
formulas. Likewise, analysis of metabolic parameters and plasma
amino acid concentrations demonstrated a safe and balanced
nutritional composition. Energetic efficiency for growth (weight)
was slightly higher in LPeHF and synbiotics compared with LPpHF
and synbiotics.
Conclusions: All tested hydrolyzed LP formulas allowed normal weight
gain without being inferior to regular protein eHF in the first 4 months of life.
This trial was registered at clinicaltrials.gov, NCT01143233.
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hood (1–3). An inverse relationship has been documented between
obesity development and breast-feeding (BF) duration suggesting
the latter’s protective role (4). Formula-fed term infants have been
found to show greater body weight gain compared with breast-fed
babies (5). Particularly the higher protein intake of formula milk has
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JPGN  Volume 66, Number 5, May 2018 Hydrolyzed Infant Formula With Reduced Protein ContentIn a systematic review on the effects of infant protein intake
and growth, 12 randomized controlled trials (RCTs) were analyzed,
and wherever possible, a meta-analysis was performed (7). The
authors conclude that ‘‘the current evidence is insufficient for
assessing the effects of reducing the protein concentration in infant
formulas on long-term outcomes, but, if confirmed, this could be a
promising intervention for reducing the risk of overweight and
obesity in children.’’
There is hardly any data available regarding the safety of
hydrolyzed formula with lower protein (LP) content (8). Moreover,
authorities do not accept the transfer of study results from one
hydrolysate to another (9). Nevertheless, in line with current
European and American prevention guidelines for allergic diseases,
infants at high-risk can be recommended a hypoallergenic (hydro-
lyzed) formula (HA) with a documented preventive effect for the
first 4 months, if BF is impossible (10–14).
The goal of this study was to investigate safety and suitability
of infant formulas with LP content using a noninferiority design. On
the basis of the only other safety study on hydrolyzed proteins,
which had already proven safety by the EFSA committee at the start
of our study, the acceptable noninferiority margin for evaluating the
daily weight gain (3.5 g/day) was derived (8). As primary end-
point, noninferiority of daily weight gain was investigated compar-
ing the LP group (LPpHF 1.9 g protein/100 kcal, allowed by
Directive 2006/141/EC) to a regular protein eHF group (2.3 g
protein/100 kcal).
In addition to aspects of the protein content, other ingredients
of human milk like oligosaccharides as well as probiotic bacteria
have been discussed as contributing to health benefits of breast-fed
infants (15–17), probiotics and prebiotics (synbiotics) were added.
Combining these aspects, the aim of this study was to
investigate noninferiority for normal growth of healthy term infants
of partial and extensively hydrolyzed formulas (pHF, eHF) with
lower hydrolyzed protein content than regularly used conventional
formulas, with or without synbiotics.
PATIENTS AND METHODS
Trial Design
The study was a parallel, prospective, randomized, con-
trolled, double-blind, intervention trial. Noninferiority with regard
to growth was tested comparing three modified intervention formu-
las to an established formula. The study was conducted according to
the principles and rules laid down in the Declaration of Helsinki and
its subsequent amendments, also in accordance with the Interna-
tional Conference on Harmonization Guidelines on Good Clinical Copyright © ESPGHAN and NA
B.A. received a travel reimbursement and honorarium from Allergopharma
for active participation in a scientific seminar. N.H. has received
speaker’s honoraria from Nestle, Milupa, Hipp, Novolac, and Baxter, is
running studies for Nestle, Hipp, and Winicker Norimed and is currently
receiving a grant (No: 15378) from the Austrian National Bank ‘‘Jubilee
Fund.’’ E.H. received a travel reimbursement and honorarium from
Nutricia and Milupa for his active participation in scientific seminars.
Analyses of energetic efficacy of infant formulae by M.F. were
performed within her research activity at the Dr. von Hauner Children‘s
Hospital Munich. M.F. is now an employee of HiPP GmbH & Co.
Vertrieb KG. A.K. has received honoraria from HiPP GmbH & Co.
Vertrieb KG. B.K. is a member of the National Breastfeeding
Committee and declares bias towards breastfeeding. The Ludwig-
Maximilians-University (LMU) of Munich Medical Centre and its
employees B.K. and C.H. had scientific and educational collaboration
with manufacturers of nutritional products for infants and children,
primarily as part of research collaboration funded by the European
Commission, the European Research Council and also with German
www.jpgn.orgPractice, and following the recommendations stated in the Consoli-
dated Standards of Reporting Trials (CONSORT) guidelines (18).
Procedures were approved by the ethics committees of all study
centers. Written informed parental consent was obtained. This trial
was registered at clinicaltrials.gov, NCT01143233. (More details
are available in the Supplementary Appendix, Supplemental Digital
Content, http://links.lww.com/MPG/B201).
All infant formulas are in accordance with relevant EU
directives (Directive 2006/141/EC) (19). Formulas were whey-
based, either extensively or partially hydrolyzed (eHF or pHF)
and differed from the regular formula in the amount of hydrolyzed
cow milk-based protein: LP formula (1.9 g protein/100 kcal) as pHF
with synbiotics, without synbiotics, eHF-LP-formula with synbio-
tics, or regular protein eHF (2.3 g protein/100 kcal; Table 1). Cur-
rently, no formula is available on the market.
For the synbiotics, Lactobacillus fermentum CECT5716 was
used as probiotic (20) and galacto-oligosaccharides (GOS) as
prebiotic. Individual amino acids (AAs) were added according to
Annex V of 2006/141/EC (Table 1).
Primary and Secondary Outcome Assessment
The study was designed as a safety study (up to 4 months of
age) with an additional follow-up visit at 12 months of age. The
primary outcome analysis was based on growth assessed up to
4 months of age, which is recommended by Scientific Committee on
Food (SCF) report 2003. The primary outcome of the study was the
average daily weight gain per day in grams (g/day) between Visit 1
(28 3 days of life) and Visit 4 (112 3 days of life) to estimate
proper growth of infants fed the lower protein hydrolyzed infant
formula. Secondary outcomes included measurements of: body
length and head circumference as well as the analysis of metabolic
parameters. To describe adverse events (AE), the following sub-
groups were regarded with special interest: atopic dermatitis, fever
episodes, and infections.
Study Population
Included were healthy term newborns<28 days of life with a
gestational age of 37 weeks and a birth weight between 2500 and
4500 g. During recruitment procedures, BF was promoted. Exclu-
sion criteria were any severe acquired or congenital illness in infants
or mothers that could potentially affect normal growth, (ongoing)
antibiotic therapy, a regular intake of supplementary synbiotics by
the child and/or BF mother, and the participation in another
clinical trial.SPGHAN. All rights reserved.
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TABLE 1. Nutritional characteristics of the formulas




Energy (kcal/100 mL) 67 67 67 67
Protein 2.3 1.9 1.9 1.9
Degree of hydrolysis 23–29% 16–22%
Peptide size distribution (weight%)
>6.000 Da: < 0.1 >20.000 Da: max. 2
3.500–6.000 Da: 0.4 5.000–20.000 Da: max. 9
1.500–3.500 Da: 12.7 1.000–5.000 Da: max 46
<1.500 Da: 86.8 <1.000 Da: max. 56
Carbohydrates 10.6 10.7 11.1 10.7
Fat 5.4 5.4 5.4 5.4
GOS (g/100 mL) — 0.3 — 0.3
Lactobacillus fermentum (cfu/g) at production — 107 — 107
Amino acids (mg/100 kcal)
Alanine 122 97 113 112
Arginine 52 65 74 75
Asparagic acid 290 221 220 218
Cysteine 54 39 37 37
Glutamic acid 488 371 317 316
Glycine 44 34 39 39
Histidine 45 45 49 48
Isoleucine 148 117 113 111
Leucine 214 188 232 230
Lysine 239 174 216 214
Methionine 44 33 36 36
Phenylalanine 69 96 107 106
Proline 176 132 97 98
Serine 127 100 73 71
Threonine 191 150 96 95
Tryptophan 36 35 36 36
Tyrosine 97 67 55 56
Valine 132 107 94 94
Values are expressed as g/100 kcal unless otherwise indicated. All values refer to raw materials. Due to technological processes and differences in raw
material, values might not exactly reflect reference values given in correspondent directive. Formulas were manufactured and provided by HiPP GmbH & Co.
Vertrieb KG (Pfaffenhofen, Germany). AA¼ amino acids; Da¼Dalton; eHf¼ extensively hydrolyzed protein formula, with a protein content of 2.3 g/
100 kcal; GOS¼ galacto-oligosaccharides; LP¼ low protein; LPeHFþSyn¼ lower protein content (1.9 g/100 kcal), extensively hydrolyzed formula with
synbiotics; LPpHF¼ LPpHF¼ lower protein content (1.9 g/100 kcal), partially hydrolyzed formula.
Individual AA were added according to Annex V of 2006/141/EC as follows: Phenylalanine and Histidine were added to both LPpHF; Phenylalanine,
Tyrosine, and Tryptophan were added to both eHF and in addition Leucine and Histidine to LPeHFþSyn; Arginine was added to all LP formulas to achieve
concentrations similar to those present in human milk.
Ahrens et al JPGN  Volume 66, Number 5, May 2018Randomization and Blinding
If parents decided not to exclusively breast-feed, despite the
recommendation, infants were randomized up to day 27 of life into
1 of 4 formula arms (Fig. 1) by a computer-generated list. Ran-
domized infants were stratified by sex and family risk of allergy
[assessed by questionnaire (21)]. Mothers were advised to feed
intervention formula as the only substitute to human milk until the
child reached the age of 16 weeks.
Study Procedure
During the baseline visit, standardized interviews were con-
ducted in order to obtain core data (infant, maternal, parental, and
‘‘allergic’’ home environment) as recommended by European
Society for Paediatric Gastroenterology Hepatology and Nutrition
(ESPGHAN) (22,23).
Parents were asked to complete a daily diary starting at Visit
1 and a 3-day record before each visit including information on Copyright © ESPGHAN and NA
824stool characteristics and digestion history, formula intake, fre-
quency of breast milk intake, and others. In case of a serious
adverse event (SAE), feeding of study formula was stopped
whenever recommended by a physician. Further details on the
study procedure are provided in the Supplemental Content and
Supplemental Figure 1 (Supplemental Digital Content, http://
links.lww.com/MPG/B201).
Sample Size
Sample size requirements were calculated using PASS 2006
(NCSS, Kaysville, Utah). Using a one-sided two-sample t-test
procedure to show noninferiority and assuming a true difference
of 0.75 g in daily weight gain (pooled SD of 5.71 g) with a
noninferiority-margin of 3.5 g/day (type 1 error of 2.5%, type
2 error of 20%) resulted in 69 infants per group. Parameters for
sample size estimation were derived from Ziegler et al (8). The
noninferiority margin assumed a weight difference between groups
of 294 g. On the basis of this trial, the lower limit of difference inSPGHAN. All rights reserved.
www.jpgn.org
* Of which n=1 infant in LPpHF and n=1 infant in Breased group was excluded from ITT analysis due to subsequently detected failure to sasfy major entry criteria.
Enrollment Assessed for eligibility (n= 503)
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FIGURE 1. Subject disposition/randomization, allocation, and follow-up of study participants in the intervention group. The final ITT population
included 361 formula-fed infants (Belgrade: n¼97; Berlin: n¼89; Bochum: n¼40; Rostock: n¼52; and Vienna: n¼83). Of these, a total of 226
infants fulfill the criteria for the PP population (eHF: n¼45; LPpHF: n¼65; LPpHFþ Syn: n¼59; LPeHF: n¼57). Of the 95 breast-fed infants, 66
infants fulfill criteria for PP population. eHF¼ extensively hydrolyzed protein formula, with a protein content of 2.3 g/100 kcal; ITT¼ intention to
treat population; PP¼per protocol; LPeHFþSyn¼ lower protein content (1.9 g/100 kcal), extensively hydrolyzed formula with synbiotics;
LPpHF¼ lower protein content (1.9 g/100 kcal), partially hydrolyzed formula.
JPGN  Volume 66, Number 5, May 2018 Hydrolyzed Infant Formula With Reduced Protein Contentweight gain of 3.5 g/day is clinically relevant. Assuming a drop-
out rate of 30%, the total number of infants per group needed for
recruitment was 100.
Statistical Analysis
The ITT population comprised all enrolled infants that
participated at least in Visit 1, including those with minor
and severe noncompliance to protocol and subjects with
missing values. The PP analysis included all infants who com-
pleted the intervention period up to 4 months of age without
severe noncompliance to the protocol. Main conclusions on
the primary efficacy parameter were based on the PP popula-
tion, intention to treat (ITT) population served as sensitivity
analysis.
Anthropometric measurements had been assessed with
descriptive statistical methods and expressed as z scores relative
to the growth standards of the World Health Organization
(WHO) for children (24). An analysis of variance model was
applied to evaluate the noninferiority of the primary outcome
(using fixed factors treatment group, center, allergy risk class,
and sex), and additionally executed for the comparison of the
other formula groups to the standard formula. One-sided 97.5%
confidence limits were derived to decide on noninferiority (Data
analysis: SAS version 9.3 (SAS Institute Inc., Cary, North
Carolina).
Details for AA data analysis, calculations on energetic
efficiency for growth (25) and further evaluation of group differ-
ences are shown in the Supplemental Content (Supplemental Digital
Content, http://links.lww.com/MPG/B201). Copyright © ESPGHAN and NA
www.jpgn.orgRESULTS
Recruitment and Study Population
Between April 2010 and November 2013, 503 healthy full-
term newborns were recruited in Germany (Berlin, Bochum,
Rostock), Austria (Vienna), and Serbia (Belgrade). Of these,
402 infants were randomized to four formula-feeding groups
(Fig. 1). The number of subjects (n¼ 69) needed to reach
statistical power was achieved for each group. One hundred
and one infants were breast-fed and served as external reference
(Fig. 1). The final ITT population included 361 formula-fed
infants. Of these, a total of 226 infants fulfilled the criteria for
the PP population.
Baseline Characteristics
Baseline characteristics did not differ between the groups
except for education, smoking behavior, and age at enrollment;
indicating more mothers smoked during pregnancy in the LPpHF
group and none in the BF group (P< 0.05), infants in the
LPeHFþSyn group were older at enrollment (P< 0.05) and
mothers of BF group had higher education (P< 0.001; Supplemen-
tal Table 1, http://links.lww.com/MPG/B201).
Weight Gain and Growth
Daily weight gain of infants receiving hydrolyzed formulas
with LP content did not differ from infants receiving the regular
protein formula eHF (Fig. 2; Supplemental Figure 2, http://
links.lww.com/MPG/B201). The difference in daily weight gainSPGHAN. All rights reserved.
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FIGURE 2. Visualization of the median absolute weight (inter quartile range, minimum and maximum; upper display) and average daily weight
gain of infants between Visit 1 (day 283) and Visit 4 (day 1123) receiving modified intervention formulas compared to the standard formula
(lower display). The BF group served as an external reference (ITT population). The symbol (

) shows proof of noninferiority. BF¼breast-feeding;
ITT¼ intention to treat.
Ahrens et al JPGN  Volume 66, Number 5, May 2018in infants receiving LPpHF compared with infants fed with regular
eHF was 2.15 g/day (CI 0.18 to inf.) for PP and 1.03 g/day (CI
1.01 to inf.) for ITT. The noninferiority was proven by confirming
that the difference in weight gain did not exceed 3.5 g/day (limit of
the one-sided 97.5% CI). Furthermore noninferiority was shown for
both LP hydrolyzed formulas containing synbiotics (LPpHFþ Syn
1.23 g/day (CI0.95 to inf.), LPeHFþSyn 2.10 g/day (CI0.30 to
inf.) for PP. Analyses for ITT resulted in comparable results
(LPpHF 1.03 g/day (CI 1.01 to inf.), LPpHFþ Syn 1.03 g/day
(CI 0.68 to inf.), LPeHFþSyn 2.25 g/day (CI 0.01 to inf.).
ANCOVA sensitivity analysis indicated a gender effect for all
group comparisons (to control). Copyright © ESPGHAN and NA
826Between Visit 1 and Visit 4, gains in weight, length and head
circumference did not differ between low- and regular protein
formula groups (Supplemental Table 2, http://links.lww.com/
MPG/B201). Anthropometric measurements, expressed as z scores
(Fig. 3), were within 1 to 1 (15th/85th percentile) throughout the
study, confirming age-appropriate development.
With regard to formula (mL/day) and caloric intake (kcal/
day), no differences were found between low- and regular protein
groups. As expected, however, protein intake was significantly
lower in all LP groups than the eHF group (P< 0.001; Supplemen-
tal Table 3, http://links.lww.com/MPG/B201). No differences in
intakes of liquids or weaning food were observed.SPGHAN. All rights reserved.
www.jpgn.org
FIGURE 3. Anthropometric measurements (weight for age, length for age, and head circumference for age) expressed as z scores (growth
standards of the WHO). z scores within1 to 1 confirm an age-appropriate development (z score¼1 equal to 15th/ 85th percentile). Results of
the total ITT population are depicted. ITT¼ intention to treat; WHO¼World Health Organization.
JPGN  Volume 66, Number 5, May 2018 Hydrolyzed Infant Formula With Reduced Protein ContentThe energetic efficiency for growth (weight) adjusted for
center showed no difference between eHF (5.51 1.23 g/
100 kcal) and LPpHF (5.64 1.31; P¼ 0.53) or LPpHFþSyn
(5.63 1.13; P¼ 0.54) but was higher in LPeHFþSyn
(6.12 2.02) compared with eHF (P¼ 0.03). No statistical
difference was observed between LPpHF and LPpHFþSyn
(P¼ 0.92), whereas the energetic efficiency for growth was Copyright © ESPGHAN and NA
www.jpgn.orghigher in LPeHFþ Syn compared with LPpHFþSyn (P¼ 0.045)
or LPpHF (P¼ 0.056).
Safety Parameters
Values for base excess (0 3 mmol), serum bicarbonate
(24 mmol/L) and plasma albumin (Visit 1: 25–46 g/L; Visit 4:SPGHAN. All rights reserved.
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Ahrens et al JPGN  Volume 66, Number 5, May 201838–54 g/L) were within normal range and did not differ between all
formula-fed groups. Infants who fed an intervention formula had
lower blood urea nitrogen values (P< 0.001) compared with con-
trols and were within normal range (6–25 mg/dL; Supplemental
Table 4, http://links.lww.com/MPG/B201).
Analysis of plasma AA profile focused on plasma levels at
Visit 4, because at this time study, formula was the sole or
predominant source of nutrition (according to study protocol PP
versus ITT analysis).
At Visit 4, significantly lower plasma concentrations of
Isoleucine (Ile), Methionine (Met), Proline (Pro), Threonine
(Thr), Valine (Val) were observed in all intervention groups
compared with eHF (Supplemental Table 5, http://links.lww.com/
MPG/B201), reflecting lower AA intake, and they approached
levels observed in BF infants. Concentrations of Pro and Val were
disproportionately decreased and even below the BF levels. Lysine
(Lys) concentration were lower in the LPeHFþSyn group com-
pared with eHF, also reflecting LP, and hence AA intakes. Plasma
Phenylalanine (Phe) concentrations were significantly increased in
all intervention groups compared with eHF.
For safety evaluation, stool characteristics were documented
and differed significantly (P< 0.001 for consistency/color/odor)
between groups. The majority of infant stools in the formula groups
were described as ‘‘soft.’’ Stools of BF infants were mostly
described as ‘‘watery.’’ At Visit 4, stool color of infants receiving
eHF, was described as ‘‘yellow’’ (60%). ‘‘Green’’ was the pre-
dominant color for all LP groups (48–60%). On study completion,
the majority of parents (formula and BF group) described stool odor
as normal (83–87%) with the other parents describing the odor as
‘‘smelly’’ or ‘‘mixed.’’ No significant differences in stool charac-
teristic were observed between infants receiving formulas with or
without the addition of synbiotics. Finally, no differences were
reported concerning reflux and vomiting.
Results of documented AEs showed no formula related risk
(Supplemental Table 6, http://links.lww.com/MPG/B201).
In total, at least one SAE (in all cases hospitalizations) have
been recorded for 47 children. Documented SAEs were unlikely
(15.3%) and not related (84.7%) to formula intake (Supplemental
Table 7, http://links.lww.com/MPG/B201).DISCUSSION
Main Findings and Comparison With Other
Studies
The results of this prospective, multicenter, randomized
intervention trial confirmed the hypothesis that healthy term
infants consuming either partially or extensively hydrolyzed for-
mula with LP—with or without the addition of synbiotics—
showed similar growth (noninferior growth) when compared with
infants fed a regular protein formula containing an extensive
hydrolysate. Findings are in agreement with the only other study
to date supporting normal growth in term infants receiving a
formula containing a lower concentrated partial protein hydroly-
sate (1.9 g/100 kcal) (8). Furthermore, studies using intact protein
have documented normal growth in infants receiving formula with
a reduced protein/energy ratio (1.8 g/100 kcal) (26–28). Likewise,
a normal weight gain of ‘‘protein-hydrolysate formula-fed
infants’’ was shown in the study by Mennella et al (29) but the
weight gain was accelerated in cow-milk formula-fed infants,
although both formulas were isocaloric and the protein hydrolysate
had a 35% higher protein content. The authors discussed this
observation especially upon underlying hypothesis that relative
to intact proteins, hydrolyzed proteins are absorbed and metabo-
lized differently (29). Copyright © ESPGHAN and NA
828Thus, our results demonstrated that all 3 formulas with
reduced contents of hydrolyzed protein, provide adequate growth
of healthy infants.
Simple comparison of the LPpHF versus LPpHFþSyn
groups, provide no indication that the addition of synbiotics may
have influenced infants’ growth, which is in line with other studies
(31,32). In addition, the effect of supplemented synbiotics espe-
cially on allergy development will be evaluated in the future when
the follow-up beyond 4 months of age has been completed.
Importantly, all 3 interventional formula groups showed
safety parameters similar to the regular formula group.
Analyzed metabolic parameters were within the reference
ranges, reflecting a balanced composition of the tested formulas.
The importance of the evaluation of formulas with regard to their
capacity to provide normal nutritional status has not least been
underlined by Hernell and Lönnerdal (32) who performed a
nutritional evaluation of protein hydrolysate formulas (with no
reduced protein content) in healthy term infants: plasma AAs,
hematology, and trace elements. They concluded that ‘‘A reduced
and more balanced amino acid content of hydrolysate formulas
may be beneficial.’’ As expected, in our study, plasma urea
nitrogen values were lower in infants receiving LP formulas,
due to the reduction in protein intake (32). Notably, plasma urea
nitrogen concentration did not fall to values of inadequate protein
intake (33).
The significant LP intake in infants receiving LP formula
resulted, at least in part, in lower plasma AA concentrations,
supporting data from previous studies (34,35) and this appears
desirable as the plasma levels are nearer to those found in BF
infants. The exception was Phe, with elevated plasma concentra-
tions in infants receiving intervention formulas compared with
controls. Phe was added to all intervention formulas to meet EU
Guidelines for Tyrþ Phe (2006/141/EC). Thus, the higher Phe
levels in infant’s blood plasma may just reflect formula compo-
sition. Our results, however, suggest that the European guideline-
based amount of Phe added to infant formula might be further
reduced while still meeting breast-fed plasma Phe concentrations.
The observed Phe plasma levels were comparable with infants
receiving a nonhydrolyzed LP formula (35) and below those
observed in infants fed a partially hydrolyzed protein formula
in previous studies (34). Lowering protein content significantly
reduced plasma threonine concentration in the LPeHFþ Syn,
thus, improving Thr status relative to BF infants. In general, it
was observed that plasma amino acid levels reflected the compo-
sition of the different formulas. Ile, Met, Pro, Thr, and Val, were
not only significantly lower in all 3 different LP groups but also
lower in the LP formulas compared with eHF. Although Pro and
Val levels were even below plasma levels in BF infants, the
median values were similar to blood levels found in infants in
previous studies who were breast-fed or received nonhydrolyzed
LP formula (25,35,36). As all formula groups showed a similar
amino acid pattern, it is worth mentioning that aromatic AAs and
branched-chain amino acids (BCAA), which have been associated
with obesity in childhood or adulthood studies (37–39), behaved
differently.
The LP content in intervention formulas was not compen-
sated for by an increased intake of formula, other liquids, or
complementary foods. Similar observations are described in other
publications focusing on LP infant formulas (5). Energetic effi-
ciency was comparable with that found in other studies in this age
group (25,40). Differences between LP groups, however, might be
related to slightly lower energy intake by LPeHFþ Syn.
Infants’ weight, length, and head circumference were com-
parable between intervention and control groups (in PP and ITT
population).SPGHAN. All rights reserved.
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This study tests different hydrolysates as part of a LP
formula. Major strengths of this study were subject randomization,
sample size, and its multicenter, multinational design. Furthermore,
major potential confounding factors were considered in the study
design and standardized anthropometric measurements were per-
formed. Small age differences at time of enrollment had no influ-
ence on study outcomes, as age was the same in all groups at
study start.
As hydrolyzed formulas differ by the degree of hydrolysis
and residual antigenicity, hydrolyzation alone does not guarantee
clinical safety and effectiveness. Consequently, each hydrolysate
needs to be tested in a clinical trial for its safety and efficacy before
use (9). A study limitation is, that only one type of control formula
with eHF has been analyzed. Nevertheless, results of this trial
indicate safety and suitability of two individual hydrolysates (exten-
sive and partial) tested.
CONCLUSIONS
In summary, this randomized intervention trial documents
that all tested lower protein hydrolyzed formulas with or without
synbiotics show noninferiority with regard to growth compared
with a regular protein extensively hydrolyzed formula in infants
during the first 4 months of life. Likewise, metabolic safety
parameters and plasma AA concentrations reflect a safe and bal-
anced nutritional composition.
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